Technological advancements in antibody engineering and production have transformed the Aurora Kinase B Antibody Market. The adoption of recombinant DNA technology and enhanced monoclonal antibody purification methods has vastly improved specificity, reproducibility, and therapeutic safety profiles.
Primary Market Drivers
-
Targeted Cancer Therapies: Increased focus on developing small-molecule inhibitors and targeted immunotherapy panels that act on cell cycle checkpoints.
-
Recombinant Antibody Adoption: Shift from traditional polyclonal production to recombinant antibodies, minimizing lot-to-lot variability in research studies.
-
AI-Driven Biomarker Discovery: Integration of artificial intelligence and next-generation sequencing (NGS) in evaluating Aurora Kinase B as a diagnostic and prognostic tumor biomarker.
